Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M570Revenue $M3.4Net Margin (%)-2,609.7Z-Score-4.3
Enterprise Value $M519EPS $-0.8Operating Margin %-2,494.0F-Score3
P/E(ttm))0Cash Flow Per Share $-0.5Pre-tax Margin (%)-2,609.7Higher ROA y-yY
Price/Book010-y EBITDA Growth Rate %-24.9Quick Ratio5.7Cash flow > EarningsY
Price/Sales1145-y EBITDA Growth Rate %-11.8Current Ratio5.7Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-67.4Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)-329.6Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M116ROI % (ttm)-167.3Gross Margin Increase y-yN

Gurus Latest Trades with OREX

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
OREXJohn Burbank 2013-12-31 Sold Out -0.15%$4.72 - $6.83
($5.61)
$ 4.42-21%Sold Out0
OREXJohn Burbank 2012-09-30 Buy 0.2%$3.77 - $7.39
($5.32)
$ 4.42-17%New holding, 750000 sh.750,000
OREXGeorge Soros 2012-06-30 Sold Out -0.03%$3.16 - $6.37
($3.76)
$ 4.4218%Sold Out0
OREXGeorge Soros 2012-03-31 Buy 0.03%$1.68 - $5.01
($3.11)
$ 4.4242%New holding, 500000 sh.500,000
OREXJean-Marie Eveillard 2010-09-30 Sold Out -0.01%$3.9 - $6.77
($4.98)
$ 4.42-11%Sold Out0
OREXJean-Marie Eveillard 2010-06-30 Add$4.05 - $7.04
($5.57)
$ 4.42-21%Add 74.07%470,000
OREXJean-Marie Eveillard 2010-03-31 Add$5.9 - $7.66
($6.55)
$ 4.42-32%Add 22.73%270,000
OREXJean-Marie Eveillard 2009-12-31 Add0.01%$6.44 - $9.39
($7.57)
$ 4.42-42%Add 83.33%220,000
OREXJean-Marie Eveillard 2009-09-30 Buy 0.01%$5.2 - $10.34
($7.89)
$ 4.42-44%New holding, 120000 sh.120,000
OREXJean-Marie Eveillard 2007-09-30 Sold Out $13.21 - $15.88
($14.5)
$ 4.42-70%Sold Out0
OREXJean-Marie Eveillard 2007-06-30 Buy $13.75 - $17.94
($16)
$ 4.42-72%New holding, 21400 sh.21,400
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

OREX is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


OREX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Hagan Joseph PSr. VP, Corporate Development 2014-09-15Buy5,000$4.69-5.76 view
NARACHI MICHAELPresident and CEO 2014-09-15Buy50,000$4.78-7.53 view
Hagan Joseph PChief Business Officer 2013-07-31Sell12,000$7.8-43.33 view
Hagan Joseph PChief Business Officer 2013-07-26Sell10,000$7.4-40.27 view
Booth Mark DChief Commercial Officer 2013-07-26Sell64,767$7.55-41.46 view
Klassen PrestonSVP, Head Global Development 2013-07-25Sell71,229$7.16-38.27 view
Klassen PrestonSVP, Head Global Development 2013-05-28Sell28,771$7.21-38.7 view
Hagan Joseph PChief Business Officer 2013-05-28Sell28,000$7-36.86 view
Booth Mark DChief Commercial Officer 2013-03-11Sell27,685$6.67-33.73 view
Booth Mark DChief Commercial Officer 2013-01-15Sell22,315$6.67-33.73 view

Press Releases about OREX :

    Quarterly/Annual Reports about OREX:

    News about OREX:

    Articles On GuruFocus.com
    Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
    Weekly CEO Sells Highlight: Orexigen Therapeutics Inc, Gas Natural Inc, The Middleby Corporation, an Jul 15 2012 
    Weekly CEO Sells Highlight: Gas Natural Inc, Encore Bancshares Inc, Staples Inc, and Orexigen Therap Jul 08 2012 
    Arena Facing Increased Pressure from Peers Apr 23 2012 
    Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 
    Vivus Could Rocket on Success of Qnexa Apr 13 2012 
    Steve Cohen Bets On Orexigen Ahead of FDA Approval Jan 31 2011 
    Orexigen Therapeutics Inc. Reports Operating Results (10-Q) Nov 04 2010 
    Orexigen Therapeutics Inc. Reports Operating Results (10-Q) Aug 06 2010 
    cooldecency99 note on OREX May 01 2010 


    More From Other Websites
    Nasdaq stocks posting largest percentage decreases Sep 22 2014
    The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation... Sep 18 2014
    Biotech Stock Roundup: Avanir Soars on Phase II Data, Orexigen's Contrave Approved Sep 17 2014
    Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference Sep 16 2014
    Insider Trading Alert - HTGC, OREX And TEP Traded By Insiders Sep 16 2014
    Shire eating disorder drug gets U.S. priority review Sep 15 2014
    OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Sep 15 2014
    Novo Nordisk's Saxenda Gets Positive Opinion for Obesity Sep 12 2014
    [video] Orexigen's anti-obesity pill wins FDA Approval Sep 12 2014
    [video] Orexigen drops in spite of FDA approval Sep 11 2014
    How Will Orexigen Therapeutics (OREX) Stock Respond to FDA's Contrave Approval? Sep 11 2014
    U.S. FDA panel: Novo Nordisk's liraglutide safe/effective for obesity Sep 11 2014
    Orexigen's Obesity Drug Contrave Approved by the FDA Sep 11 2014
    FDA approves weight-loss drug Contrave Sep 11 2014
    Orexigen's Obesity Pill is Approved and Stock Falls. Don't be Surprised Sep 11 2014
    [video] Orexigen's obesity pill Sep 11 2014
    [$$] FDA Approves Weight-Loss Drug Sep 11 2014
    Long-awaited diet pill gets U.S. approval Sep 11 2014
    FDA approves weight-loss drug Contrave Sep 11 2014
    Orexigen Therapeutics Call scheduled for 8:30 am ET today Sep 11 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK